Guy Mayer

This paper introduces FibrilPaints, a modular peptide system for selective amyloid binding and manipulation, showing that sequence variations affect binding affinity while allowing functional modifications.

FibrilPaint1 measures Tau amyloid fibril length in fluids using fluorescence and microfluidics, enabling diagnostic and research applications in neurodegenerative diseases.

This study shows that SARS-CoV-2 nucleocapsid protein binds to uninfected cells, triggering antibody-mediated complement activation in COVID-19 patients.

The paper demonstrates that FP20 recruits the ubiquitin-proteasome system to Tau amyloid fibrils, enabling their degradation and offering a strategy for targeting amyloid diseases.